July 28, 2014
Financial Times: Global push can bring remedies within reach of all who need them
Stefan Wiktor, team leader of the WHO's global hepatitis program, and Gottfried Hirnschall, director of WHO's HIV department
"We are witnessing a remarkable transformation in the treatment of hepatitis C virus infection (HCV). Intensive research is beginning to yield a number of new 'direct-acting antiviral' medicines that have shortened and simplified treatment of HCV and produced high cure rates. This offers a real possibility that we can dramatically reduce the numbers of people who die each year from liver cancer and cirrhosis because of HCV infection. ... An estimated 500,000-700,000 people die each year from liver cancer and cirrhosis caused by HCV. The new treatments provide a remarkable opportunity to cut the number significantly and prevent new infections. This can only be realized if there is a global effort to make the medicines affordable and to invest in health care services in order that the medicines can reach those who need them" (7/27).
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|PrEP Prescriptions Rise Sharply, but Unequally, in New York City|
|A Review of Late-Stage HIV Antiretroviral Candidates at IDWeek 2017|
|How to Reverse Implicit Bias in HIV Care: 6 Steps to Take Today|
|Free Your (and Carl's) Mind: An Open Letter to Anthony Fauci About HIV Prevention Research Priorities|
|This Week in HIV Research: Injectable PrEP Shows Promise in New Study|
|Let's Advance the Conversation Among Black Women on HIV and PrEP|